middle.news
Orthocell Expands Remplir™ Reach with Early Canadian Approval
9:08am on Wednesday 30th of April, 2025 AEST
•
Healthcare
Read Story
Orthocell Expands Remplir™ Reach with Early Canadian Approval
9:08am on Wednesday 30th of April, 2025 AEST
Key Points
Health Canada grants Medical Device Licence for Remplir™
Canadian nerve repair market valued at US$75 million added to approved markets
Total addressable market for Remplir™ now estimated at US$1.8 billion
Orthocell to appoint local distributors in Canada with sales starting in second half of 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Orthocell (ASX:OCC)
OPEN ARTICLE